SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rezolve AI Plc operates in the mobile commerce industry with its cutting-edge engagement platform powered by artificial intelligence and machine learning. It develops AI-based mobile commerce and engagement solutions, simplifying the purchasing process by providing relevant information and facilitating seamless transactions with a single tap. The company enables retailers, brands, and manufacturers to create dynamic connections with consumers across mobile and desktop devices. Rezolve Ai was founded in 2016 and is headquartered in London, the United Kingdom.

Rezolve AI PLC .

Rezolve AI Limited

Rezolve AI (RZLV) is trending as investors discuss the implications of a recent $200 million private placement just days before earnings, with community members debating whether it signals confidence or dilution. Some investors express concerns about the timing and potential stock impact, while others view it as a strategic move for growth and expansion. The community is also actively discussing the upcoming earnings report and potential partnerships.

BTQ Technologies Corp

BTQ is trending as investors discuss the potential impact of a $300 million registration for dilution after its NASDAQ debut, with some expressing disappointment and others viewing it as a long-term buying opportunity. Community members are debating the company's valuation and revenue prospects in the quantum cybersecurity space, while awaiting news about Robinhood availability. Some investors remain bullish, citing a deal with Danal and the potential for BTQ to become a leader in quantum-safe technology.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending amid discussions about potential market volatility related to upcoming options expirations and macroeconomic factors. Community members are actively debating potential price movements, with some anticipating a bullish "Uptober" and others bracing for further downside. Broader conversations include Bitcoin's correlation with traditional markets and its role as a store of value.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the Materials and Magnetics segments. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is trending as investors discuss the stock's recent price action and potential catalysts, including government funding and rare earth demand. Community members are debating entry points, technical levels, and the impact of broader market conditions. Some traders are expressing concerns about potential shorts and government funding, while others remain bullish on the company's long-term prospects in the rare earth sector.

The project is a derivative of Fartcoin. The Fartcoin deployer has deployed this token because the President at Bone Fide Wealth tweeted about "A client just called and asked me if there’s going to be a Fartcoin ETF this year." Since the Elon narrative is has been running this one has come to existence. The token is following different narratives like Fartcoin, SPX500 and other big memes following the Trump narrative.

Elon Trump Fart

ETF500.X is trending as the community rallies behind it, touting it as the first ETF on Solana. Many are calling for accumulation and holding, anticipating a meme season and significant gains. Some users are expressing concerns, while others highlight the strength and potential of the community-driven fund.

Electronic Arts, Inc. engages in the development, marketing, publication, and distribution of games, content, and services for game consoles, PCs, mobile phones, and tablets. The company develops and publishes games and services across various genres, such as sports, first-person shooter, action, role-playing, and simulation primarily under the Battlefield, The Sims, Apex Legends, Anthem, Need for Speed, and Plants v. Zombies brands, and license games, including FIFA, Madden NFL, and Star Wars brands. The firm also provides advertising services and licenses its games to third parties to distribute and host its games. It markets and sells its games and services through digital distribution channels, as well as through retail channels, such as mass-market retailers, electronics specialty stores, and game software specialty stores. The company was founded by William M. Hawkins III and William Gordon in 1982 and is headquartered in Redwood City, CA.

Electronic Arts, Inc.

Electronic Arts stock is trending due to reports that the videogame giant may go private in a deal potentially valued at $50 billion, with Silver Lake and Saudi Arabia's Public Investment Fund mentioned as part of the investor consortium. The community is actively discussing the potential deal's impact on game quality and the future direction of EA's popular franchises, with some expressing hope for improved games if the deal goes through.

Gyrodyne LLC engages in the management of a portfolio of medical office and industrial properties. Its properties include Flowerfield, Port Jefferson Professional Park, Courtland Medical Center, and Grove. The company was founded by Peter James Papadakos in 1946 and is headquartered in St. James, NY.

Gyrodyne LLC

GYRO is trending due to news of a land sale agreement potentially boosting its NAV, sparking interest in its low float. The community is discussing potential for a significant price increase, with some eyeing a breakout and possible short squeeze. Some traders are comparing it to other low float runners and highlighting the company's liquidation plans.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave ($CRWV) is trending due to a recently announced contract expansion with OpenAI, though the stock's price reaction has been muted, sparking debate about market skepticism and potential overvaluation. Community members are actively discussing potential manipulation and future price movements, with some expressing concerns about debt levels and insider selling. Despite the positive news, some traders are wary, citing technical indicators and broader market conditions.

Take-Two Interactive Software, Inc. engages in the development, publishing, and marketing of interactive software games. Its products are designed for console systems, handheld gaming systems, and personal computers, including smart phones and tablets, and are delivered through physical retail, digital download, online platforms, and cloud streaming services. The company was founded by Ryan A. Brant in 1993 and is headquartered in New York, NY.

Take-Two Interactive Software, Inc.

Take-Two Interactive is trending as community members discuss its potential following news of Electronic Arts exploring going private, with some suggesting mergers within the gaming sector. Investors are weighing the potential impact of the upcoming GTA 6 release, debating whether its success is already factored into the stock's valuation. Bullish sentiment remains due to anticipation for GTA 6 and the belief it will drive significant revenue.

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Enanta Pharmaceuticals Inc

$ENTA is trending as investors discuss upcoming Phase 2 data on their RSV treatment, expected on Monday, sparking speculation of positive results and a potential rocket move; the community also highlights the company's strong financial position and potential for significant gains in the antiviral space.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Beats Revenue Estimates

Taysha Gene Therapies (TSHA) delivered earnings and revenue surprises of -28.57% and +15.73%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates

Amphastar (AMPH) delivered earnings and revenue surprises of +19.72% and +2.69%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q2 Earnings? What You Should Know

Taysha Gene Therapies (TSHA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Taysha Gene Therapies (TSHA) Moves to Buy: Rationale Behind the Upgrade

Taysha Gene Therapies (TSHA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Personalis (PSNL) Surges 14.2%: Is This an Indication of Further Gains?

Personalis (PSNL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Retail buzz around Taysha Gene Therapies Inc surged Tuesday after the company released new clinical results from its TSHA-102 trial for Rett syndrome.Taysha Gene Therapies shares dipped 0.2% to close at $2.78 on Tuesday, before gaining 0.7% to $2.8 in after-hours trading.During its Reveal Phase 1/2 trials, the company presented recent cohort data for TSHA-102, which administered high and low doses to adolescent,&nbsp;adult, and pediatric patients&nbsp;through lumbar intrathecal delivery.Caregiver-reported improvements in developmental milestones supported Taysha’s alignment with the U.S. Food and Drug Administration (FDA) on the primary endpoint for the pivotal Part B trial of TSHA-102.Previously released preclinical data demonstrated broad biodistribution of AAV9 gene therapy vectors across brain and spinal cord regions in non-human primates.Taysha will present these findings in three oral presentations and a poster session at the 2025 International Rett Syndrome Foundation (IRSF) Scientific Meeting in Boston, June 9-11.Canaccord Genuity raised its price target on Taysha shares to $11 from $9, while maintaining a ‘Buy’ rating, citing positive longer-term low-dose follow-up and initial high-dose data disclosed by the company.&nbsp;The research firm also increased its assigned probability of success (POS) for TSHA-102 to 75% from 50%.Canaccord’s updated model also factored in the recently announced approximately $200 million offering via a combination of shares and prefunded warrants.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘high’ message volume.One user noted that it is unusual for a stock to increase during an offering, welcoming Taysha as an exception.&nbsp;<stembedurl>https://stocktwits.com/KING_OF_BIO/message/616691905</stembedurl>Another user highlighted that all price targets for Taysha have been raised.<stembedurl>https://stocktwits.com/strategicmind/message/616553737</stembedurl>The stock has risen 50.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail Buzz Surges Around Taysha Gene Therapies After Positive Rett Syndrome Trial Data

Canaccord Genuity raised its price target on Taysha Gene Therapies to $11 from $9, citing improved clinical data and increased confidence in the company’s TSHA-102 program. 

Equity

Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Tops Revenue Estimates

Advance Auto Parts Posts Weak Results, Joins Harrow, Taysha Gene Therapies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Trump Rally Fizzles: Futures Drop As Dollar, Yields Extend Surge

Trump Rally Fizzles: Futures Drop As Dollar, Yields Extend Surge

 The torrid five-day rally that pushed the S&P 500 to its 51st record close above 6,000 on Monday has finally reversed...

Analysts Are Bullish on Top Healthcare Stocks: Beam Therapeutics (BEAM), Taysha Gene Therapies (TSHA)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Beam Therapeutics (BEAM Research Report) and Taysha Gene Therapies...

Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.

Taysha Gene Therapies Inc

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.09	--	--	N/A
Q2 '25	-$0.08	-$0.09	-15.57%	MISSED
Q1 '25	-$0.09	-$0.08	8.68%	BEAT
Q4 '24	-$0.08	-$0.07	13.91%	BEAT
Q3 '24	-$0.09	-$0.10	-15.31%	MISSED

TSHA
Taysha Gene Therapies Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest TSHA News

TSHA Taysha Gene Therapies Inc